- Home
- PIII vs ELOX Comparison
PIII vs ELOX Comparison
Compare PIII & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PIII | ELOX |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | 320 | 7 |
| Industry | Medical/Nursing Services | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.5M | 43.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PIII | ELOX |
|---|---|---|
| Price | $9.86 | $12.47 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | 25.2K | ★ 42.4K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.67 | N/A |
| Revenue Next Year | $2.36 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.52 | $10.00 |
| 52 Week High | $16.89 | $15.00 |
Technical Indicators
Market Signals| Indicator | PIII | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 46.16 | 41.94 |
| Support Level | $9.95 | $10.51 |
| Resistance Level | $12.70 | $14.43 |
| Average True Range (ATR) | 0.85 | 1.75 |
| MACD | -0.09 | 0.05 |
| Stochastic Oscillator | 15.48 | 30.16 |
Price Performance
Historical ComparisonAbout PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About ELOX Eloxx Pharmaceuticals Inc. Common Stock
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.